| Dr Caitlin Judith Hardy, MD | |
|
1 Cooper Plz, Camden, NJ 08103 | |
| (856) 342-2390 | |
| Not Available |
| Full Name | Dr Caitlin Judith Hardy |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 17 Years |
| Location | 1 Cooper Plz, Camden, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962692806 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Atlanticare Regional Medical Center | Atlantic city, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Atlantic Medical Imaging | 0345215141 | 99 |
| Atlantic Radiologists Professional Association Llc | 3678621620 | 64 |
| Ami Atlanticare Llc | 7113073263 | 60 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of Hodgkin lymphoma (HL). The Company is currently investigating pralatrexate in a number of ongoing studies, including a Phase 2 clinical study in patients with relapsed or refractory non-Hodgkin lymphoma or Hodgkin lymphoma.
Disease-causing bacteria stink - literally - and the odor released by some of the nastiest microbes has become the basis for a faster and simpler new way to diagnose blood infections and finger the specific microbe, scientists reported here today at the 246th National Meeting & Exposition of the American Chemical Society (ACS), the world's largest scientific society.
ChromaDex Corporation, a leader in phytochemical reference standards and contract research, today announced financial results for the Fiscal Year ending January 2, 2010. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (U.S. GAAP), ChromaDex announced a net loss attributable to common stockholders of $0.03 per share for the one year period ended January 2, 2010. As of January 2, 2010, cash, cash equivalents, and marketable securities totaled $471,378.
A study of more than 2,000 patients by researchers at Mayo Clinic's campus in Jacksonville, Florida, has dispelled the myth that cancer biopsies cause cancer to spread. In the Jan. 9 online issue of Gut, they show that patients who received a biopsy had a better outcome and longer survival than patients who did not have a biopsy.
› Verified 7 days ago
| Entity Name | Radiology Affiliates Of Central New Jersey P C |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811994791 PECOS PAC ID: 1759277239 Enrollment ID: O20040330000560 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of Hodgkin lymphoma (HL). The Company is currently investigating pralatrexate in a number of ongoing studies, including a Phase 2 clinical study in patients with relapsed or refractory non-Hodgkin lymphoma or Hodgkin lymphoma.
Disease-causing bacteria stink - literally - and the odor released by some of the nastiest microbes has become the basis for a faster and simpler new way to diagnose blood infections and finger the specific microbe, scientists reported here today at the 246th National Meeting & Exposition of the American Chemical Society (ACS), the world's largest scientific society.
ChromaDex Corporation, a leader in phytochemical reference standards and contract research, today announced financial results for the Fiscal Year ending January 2, 2010. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (U.S. GAAP), ChromaDex announced a net loss attributable to common stockholders of $0.03 per share for the one year period ended January 2, 2010. As of January 2, 2010, cash, cash equivalents, and marketable securities totaled $471,378.
A study of more than 2,000 patients by researchers at Mayo Clinic's campus in Jacksonville, Florida, has dispelled the myth that cancer biopsies cause cancer to spread. In the Jan. 9 online issue of Gut, they show that patients who received a biopsy had a better outcome and longer survival than patients who did not have a biopsy.
› Verified 7 days ago
| Entity Name | Cooper University Radiology Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336188291 PECOS PAC ID: 6305838764 Enrollment ID: O20040402001110 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of Hodgkin lymphoma (HL). The Company is currently investigating pralatrexate in a number of ongoing studies, including a Phase 2 clinical study in patients with relapsed or refractory non-Hodgkin lymphoma or Hodgkin lymphoma.
Disease-causing bacteria stink - literally - and the odor released by some of the nastiest microbes has become the basis for a faster and simpler new way to diagnose blood infections and finger the specific microbe, scientists reported here today at the 246th National Meeting & Exposition of the American Chemical Society (ACS), the world's largest scientific society.
ChromaDex Corporation, a leader in phytochemical reference standards and contract research, today announced financial results for the Fiscal Year ending January 2, 2010. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (U.S. GAAP), ChromaDex announced a net loss attributable to common stockholders of $0.03 per share for the one year period ended January 2, 2010. As of January 2, 2010, cash, cash equivalents, and marketable securities totaled $471,378.
A study of more than 2,000 patients by researchers at Mayo Clinic's campus in Jacksonville, Florida, has dispelled the myth that cancer biopsies cause cancer to spread. In the Jan. 9 online issue of Gut, they show that patients who received a biopsy had a better outcome and longer survival than patients who did not have a biopsy.
› Verified 7 days ago
| Entity Name | Atlantic Medical Imaging |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396771556 PECOS PAC ID: 0345215141 Enrollment ID: O20040826000336 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of Hodgkin lymphoma (HL). The Company is currently investigating pralatrexate in a number of ongoing studies, including a Phase 2 clinical study in patients with relapsed or refractory non-Hodgkin lymphoma or Hodgkin lymphoma.
Disease-causing bacteria stink - literally - and the odor released by some of the nastiest microbes has become the basis for a faster and simpler new way to diagnose blood infections and finger the specific microbe, scientists reported here today at the 246th National Meeting & Exposition of the American Chemical Society (ACS), the world's largest scientific society.
ChromaDex Corporation, a leader in phytochemical reference standards and contract research, today announced financial results for the Fiscal Year ending January 2, 2010. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (U.S. GAAP), ChromaDex announced a net loss attributable to common stockholders of $0.03 per share for the one year period ended January 2, 2010. As of January 2, 2010, cash, cash equivalents, and marketable securities totaled $471,378.
A study of more than 2,000 patients by researchers at Mayo Clinic's campus in Jacksonville, Florida, has dispelled the myth that cancer biopsies cause cancer to spread. In the Jan. 9 online issue of Gut, they show that patients who received a biopsy had a better outcome and longer survival than patients who did not have a biopsy.
› Verified 7 days ago
| Entity Name | Atlantic Radiologists Professional Association Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841438728 PECOS PAC ID: 3678621620 Enrollment ID: O20090430000174 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of Hodgkin lymphoma (HL). The Company is currently investigating pralatrexate in a number of ongoing studies, including a Phase 2 clinical study in patients with relapsed or refractory non-Hodgkin lymphoma or Hodgkin lymphoma.
Disease-causing bacteria stink - literally - and the odor released by some of the nastiest microbes has become the basis for a faster and simpler new way to diagnose blood infections and finger the specific microbe, scientists reported here today at the 246th National Meeting & Exposition of the American Chemical Society (ACS), the world's largest scientific society.
ChromaDex Corporation, a leader in phytochemical reference standards and contract research, today announced financial results for the Fiscal Year ending January 2, 2010. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (U.S. GAAP), ChromaDex announced a net loss attributable to common stockholders of $0.03 per share for the one year period ended January 2, 2010. As of January 2, 2010, cash, cash equivalents, and marketable securities totaled $471,378.
A study of more than 2,000 patients by researchers at Mayo Clinic's campus in Jacksonville, Florida, has dispelled the myth that cancer biopsies cause cancer to spread. In the Jan. 9 online issue of Gut, they show that patients who received a biopsy had a better outcome and longer survival than patients who did not have a biopsy.
› Verified 7 days ago
| Entity Name | Ami Atlanticare Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275762023 PECOS PAC ID: 7113073263 Enrollment ID: O20090915000606 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of Hodgkin lymphoma (HL). The Company is currently investigating pralatrexate in a number of ongoing studies, including a Phase 2 clinical study in patients with relapsed or refractory non-Hodgkin lymphoma or Hodgkin lymphoma.
Disease-causing bacteria stink - literally - and the odor released by some of the nastiest microbes has become the basis for a faster and simpler new way to diagnose blood infections and finger the specific microbe, scientists reported here today at the 246th National Meeting & Exposition of the American Chemical Society (ACS), the world's largest scientific society.
ChromaDex Corporation, a leader in phytochemical reference standards and contract research, today announced financial results for the Fiscal Year ending January 2, 2010. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (U.S. GAAP), ChromaDex announced a net loss attributable to common stockholders of $0.03 per share for the one year period ended January 2, 2010. As of January 2, 2010, cash, cash equivalents, and marketable securities totaled $471,378.
A study of more than 2,000 patients by researchers at Mayo Clinic's campus in Jacksonville, Florida, has dispelled the myth that cancer biopsies cause cancer to spread. In the Jan. 9 online issue of Gut, they show that patients who received a biopsy had a better outcome and longer survival than patients who did not have a biopsy.
› Verified 7 days ago
| Entity Name | Imaging Group Of Delaware Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164421574 PECOS PAC ID: 0547152472 Enrollment ID: O20170512000055 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of Hodgkin lymphoma (HL). The Company is currently investigating pralatrexate in a number of ongoing studies, including a Phase 2 clinical study in patients with relapsed or refractory non-Hodgkin lymphoma or Hodgkin lymphoma.
Disease-causing bacteria stink - literally - and the odor released by some of the nastiest microbes has become the basis for a faster and simpler new way to diagnose blood infections and finger the specific microbe, scientists reported here today at the 246th National Meeting & Exposition of the American Chemical Society (ACS), the world's largest scientific society.
ChromaDex Corporation, a leader in phytochemical reference standards and contract research, today announced financial results for the Fiscal Year ending January 2, 2010. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (U.S. GAAP), ChromaDex announced a net loss attributable to common stockholders of $0.03 per share for the one year period ended January 2, 2010. As of January 2, 2010, cash, cash equivalents, and marketable securities totaled $471,378.
A study of more than 2,000 patients by researchers at Mayo Clinic's campus in Jacksonville, Florida, has dispelled the myth that cancer biopsies cause cancer to spread. In the Jan. 9 online issue of Gut, they show that patients who received a biopsy had a better outcome and longer survival than patients who did not have a biopsy.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Caitlin Judith Hardy, MD 1 Federal St Ste Sw200, Camden, NJ 08103-1155 Ph: (856) 356-4924 | Dr Caitlin Judith Hardy, MD 1 Cooper Plz, Camden, NJ 08103 Ph: (856) 342-2390 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of Hodgkin lymphoma (HL). The Company is currently investigating pralatrexate in a number of ongoing studies, including a Phase 2 clinical study in patients with relapsed or refractory non-Hodgkin lymphoma or Hodgkin lymphoma.
Disease-causing bacteria stink - literally - and the odor released by some of the nastiest microbes has become the basis for a faster and simpler new way to diagnose blood infections and finger the specific microbe, scientists reported here today at the 246th National Meeting & Exposition of the American Chemical Society (ACS), the world's largest scientific society.
ChromaDex Corporation, a leader in phytochemical reference standards and contract research, today announced financial results for the Fiscal Year ending January 2, 2010. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (U.S. GAAP), ChromaDex announced a net loss attributable to common stockholders of $0.03 per share for the one year period ended January 2, 2010. As of January 2, 2010, cash, cash equivalents, and marketable securities totaled $471,378.
A study of more than 2,000 patients by researchers at Mayo Clinic's campus in Jacksonville, Florida, has dispelled the myth that cancer biopsies cause cancer to spread. In the Jan. 9 online issue of Gut, they show that patients who received a biopsy had a better outcome and longer survival than patients who did not have a biopsy.
› Verified 7 days ago
Thomas Jonathan Presenza, D.O. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Radiology Dept, Camden, NJ 08103 Phone: 856-342-2380 Fax: 856-365-0472 | |
Allison Solish Gittens, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, B23, Camden, NJ 08103 Phone: 856-342-2588 | |
Dr. Maria Christina Sciotto, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 856-342-2000 | |
Robyn G Roth, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 856-342-2380 | |
Dr. Todd Loring Siegal, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Cooper University Radiology, Pc, Camden, NJ 08103 Phone: 856-342-2383 Fax: 856-365-0472 | |
Dr. Stuti Ahlawat, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: Two Cooper Plaza 400 Haddon Ave, Camden, NJ 08103 Phone: 855-632-2667 Fax: 856-735-6467 | |
Vivek Sehgal, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 888-499-8779 |